Dynavax Technologies (NASDAQ:DVAX) Upgraded by StockNews.com to Buy

StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a hold rating to a buy rating in a report published on Monday morning.

Other equities research analysts also recently issued research reports about the company. HC Wainwright restated a buy rating and set a $29.00 price objective on shares of Dynavax Technologies in a report on Thursday, May 9th. The Goldman Sachs Group began coverage on shares of Dynavax Technologies in a report on Thursday, February 1st. They set a neutral rating and a $20.00 price objective on the stock. Finally, William Blair reiterated an outperform rating on shares of Dynavax Technologies in a report on Friday, February 23rd. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $25.33.

Dynavax Technologies Stock Performance

Shares of DVAX opened at $11.88 on Monday. Dynavax Technologies has a one year low of $10.48 and a one year high of $15.15. The company has a market cap of $1.55 billion, a PE ratio of 198.00 and a beta of 1.30. The stock has a 50-day moving average of $11.76 and a 200-day moving average of $12.83. The company has a debt-to-equity ratio of 0.36, a current ratio of 15.20 and a quick ratio of 14.10.

Insider Activity at Dynavax Technologies

In other news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 2.98% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of DVAX. Charles Schwab Investment Management Inc. increased its position in shares of Dynavax Technologies by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,081,789 shares of the biopharmaceutical company’s stock valued at $15,978,000 after acquiring an additional 95,690 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Dynavax Technologies by 20.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,359,729 shares of the biopharmaceutical company’s stock valued at $20,083,000 after purchasing an additional 231,731 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Dynavax Technologies by 8.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 80,820 shares of the biopharmaceutical company’s stock valued at $1,194,000 after purchasing an additional 6,339 shares during the last quarter. Teacher Retirement System of Texas raised its stake in shares of Dynavax Technologies by 4.7% during the 3rd quarter. Teacher Retirement System of Texas now owns 36,484 shares of the biopharmaceutical company’s stock worth $539,000 after purchasing an additional 1,652 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Dynavax Technologies by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 9,146,891 shares of the biopharmaceutical company’s stock worth $135,100,000 after buying an additional 270,730 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.